6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026

COMMISSION FILE NUMBER 001-34041

Evotec SE(Translation of registrant’s name into English)

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On January 1, 2026, Evotec SE (the “Company”) issued a press release announcing the appointment of Dr. Sarah Fakih as Head of Global Communications and Investor Relations attached hereto as Exhibit 99.1.

EXHIBIT INDEX

SIGNATURE

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 1, 2026

Exhibit 99.1

Evotec appointsDr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations

Hamburg,Germany, January 1, 2026:

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Dr. Fakih will lead Evotec’s newly integrated Global Communications and Investor Relations function.

Reporting directly to CEO Dr. Christian Wojczewski, she will bring together both teams to strengthen alignment, clarity and engagement across stakeholders. The integration of Communications and Investor Relations supports Evotec’s focus on a clear and consistent articulation of its strategy, scientific leadership and value creation. The appointment follows the departure of Volker Braun, who successfully led Evotec’s Investor Relations and ESG function over the past five years.

Dr. ChristianWojczewski, Chief Executive Officer of Evotec, said: “Clear and credible communication is essential as we continue to execute our strategy. Sarah’s extensive experience across science, investor relations and corporate communications makes her ideally suited to this role. I would like to thank Volker for his dedicated contributions to our investor relations and ESG during the past five years and wish him all the best for the future.”

Dr. Fakih brings more than 15 years of experience in life sciences, with a strong leadership track record in capital markets strategy and corporate messaging. She has held senior roles at U.S. listed companies, including QIAGEN, MorphoSys, and most recently at CureVac. She holds a PhD in Chemistry.

About EvotecSE

Evotec is alife science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driveninnovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertisespans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular PatientDatabases, PanOmics and iPSC-based disease modeling.

With flexiblepartnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions,and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategicpartnerships, combining scientific excellence with operational agility.

Page 1 of 2

Through Just – Evotec Biologics, we redefine biologicsdevelopment and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietaryR&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases,neurology, and immunology.

Evotec’s global team of more than 4,800experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence.Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement containsforward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Wordssuch as “anticipate,” “believe,” “could,” “estimate,” “expect,”“intend,” “may,” “might,” “plan,” “potential,” “should,”“target,” “would” and variations of such words and similar expressions are intended to identifyforward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA andunpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations andassumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectationswill prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions andestimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control ofEvotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to anyforward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any changein events, conditions or circumstances on which any statement is based.

For further information, please contact:Investor Relations and Media Contact

Dr. Sarah Fakih

EVP Head of Global Communications & InvestorRelations

[email protected]

Page 2 of 2